LoginSubscribe DatabaseScreen Shots


enGene Announces NRC-IRAP Funding and Convertible Note Financing

TechFinance.ca News Service
Wednesday June 10, 2009

enGene Inc., a privately held biotechnology company developing an innovative platform technology for the treatment ...



[ ... to read the whole article, subscription is required ... ]



... ... ble the company to achieve several key milestones in the path to human clinical trials for its Gut-Epithelial cell Mo...


To read this or any other article, or trial test our database, please try our 7 days or 1 month subscription, Click Here for Details.

Copyright © 2003-2010 TFmedia Corporation. All rights reserved.
Any copying, republication or redistribution of TFmedia content, including by framing or similar means, is expressly prohibited without prior written consent.

Company Deals and People
Date
Title
Type
2010/3/27
EnGene Completes Bridge Financing
Financing
2010/3/4
EnGene Closes Bridge Financing
Financing
2008/2/7
A. Sinclair Dunlop
Director
2008/2/6
enGene Closes Series A Financing
Financing
2006/12/13
EnGene Completes Bridge Financing
Financing
2006/3/7
enGene Secures Further Funding to 2nd Round
Financing
2005/12/14
enGene Secures Additional Funding to 2nd Round
Financing
2004/11/17
R. Hector MacKay-Dunn, QC
Director
2004/11/17
L. Jack Wood, Chairman
Director
2004/11/3
enGene Adds Additional Funding to 2nd Round
Financing
2004/3/16
Eric A. Adams, President & CEO
Management
2004/3/16
Anthony T. Cheung, Co-founder, Chief Scientific Officer
Management
2003/12/31
enGene Closes Second Round of Financing
Financing
2001/8/15
enGene Completes First Round of Financing
Financing
2001/7/30
Francis J. Gargiulo
Director
2001/2/7
Timothy J. Keiffer, VP, Research
Management

 
enGene Inc.
Privately-held
» To this firm page « (subscriber only)
Suite 100 - 2386 East Mall
Vancouver, BC   V6T 1Z3
Tel:  (604) 221-4362
Fax:  (604) 221-4369
http://www.engene.ca
Sector - Biotechnology, Biopharmaceuticals
Business Description
enGene is a preclinical-stage biotech company developing a unique method of protein drug delivery called GEMS™ (Gut Endocrine-cell Modification System). GEMS™-Insulin enables the patients' own cells to produce insulin in a regulated, meal-dependant fashion resulting in physiologic control of blood glucose levels. Other potential applications for GEMS™ include inflammatory bowel disease, obesity, anemia, and hemophilia.


Company News
enGene Announces NRC-IRAP Funding and Convertible Note Financing 2009/6/10
enGene Closes Series A Round of Financing 2008/3/17